Pasithea Therapeutics Corp KTTA

$0.40 0.00 (-0.65%)

Valuation

Market cap
13,362,000
Revenue TTM
$0
Net income TTM
$-20,430,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
649,400
Avg volume
230,534
Day's range
$0.37 – $0.43
Shares out
33,414,000
Stochastic %K
34%
Beta
0.34
Analysts
Sell
Price target
$3.00

Price

Company profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven...

Show more

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
786 977 3380
Website
https://www.pasithea.com
Address
1111 Lincoln Road, Suite 500, Miami Beach, United States

Latest news

Stocktwits

BioTuesdays Oct 23, 3:29 PM
$KTTA has announced updated safety, tolerability, and preliminary efficacy data from its ongoing Phase 1 dose-escalation study of PAS-004 monotherapy in a heavily pre-treated population of patients with MAPK pathway-driven advanced solid tumors harboring RAS, NF1 or RAF mutations, including patients who have failed prior BRAF/MEK inhibitor treatment. https://biotuesdays.com/2026/10/23/pasithea-reports-updated-phase-1-data-for-pas-004-in-solid-tumors/
0 replies
jcme Oct 23, 2:33 PM
$KTTA https://finance.yahoo.com/healthcare/articles/pasithea-therapeutics-announces-positive-pas-131500493.html
1 replies
jskstocks Oct 23, 2:08 PM
$KTTA wow this is criminal manipulation
0 replies
mtrad03 Oct 23, 1:53 PM
$KTTA phenomenal results in clinicals - presented today
0 replies
Sashko2018 Oct 23, 1:18 PM
$KTTA I sell
0 replies
Rayvio_News_Filter Oct 23, 1:17 PM
$KTTA 🏥 Pasithea Therapeutics announced positive Phase 1 data for PAS-004 in advanced cancer, showing prolonged stable disease in four heavily pretreated patients for over 300 days, including two on once-daily treatment for over 500 days, with no Grade 3 treatment-related adverse events.
0 replies
Stock_Catcher Oct 23, 1:15 PM
$KTTA Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
0 replies
Soonerjosh03 Oct 21, 5:27 PM
$KTTA it’s curling back up
0 replies